Savara Inc (SVRA)

$2.39 +0.09 (3.91%)
Market Cap 397.53M
Revenue (ttm) 0.00
Net Income (ttm) -95.88M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.20
Volume 1,084,200
Avg Vol 1,740,880
Day's Range N/A - N/A
Shares Out 172.84M
Stochastic %K 79%
Beta 0.31
Analysts Strong Sell
Price Target $7.19

Company Profile

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in 2007 and is headquartered in Langhorne, Pennsylvania.

Industry: Biotechnology
Sector: Healthcare
Phone: 512 614 1848
Address:
1717 Langhorne Newtown Road, Suite 300, Langhorne, United States
TheThroatSlasher
TheThroatSlasher Jul. 7 at 6:20 PM
$SVRA I can’t believe this company is still operating. It’s a toilet full of diarrhea- a bowl full of liquid turds! Wipe quick & flush it
0 · Reply
Spacemonkey1
Spacemonkey1 Jul. 1 at 9:24 PM
$SVRA starting to wonder if the management team is trying to prolong things to continue getting their salaries, stock options, and bonuses.
3 · Reply
RunnerSignals
RunnerSignals Jun. 30 at 8:17 PM
comeback alert $SVRA $GMRE $CRVS $OMI $CLDX all hit the dumps midday but bounced back strong to close higher
0 · Reply
MGeronimo
MGeronimo Jun. 23 at 8:41 PM
$SVRA IN AT 2.16 on insider buying
0 · Reply
Whiskey1679
Whiskey1679 Jun. 23 at 10:57 AM
Whiskey's Picks just posted. See my Pinned post for today's picks! Premarket Gappers: $IMPP $SVRA $NNNN $SKYE $ZETA
0 · Reply
TheThroatSlasher
TheThroatSlasher Jun. 12 at 1:07 PM
$SVRA this is a turd A slippery greasy stinky turd It was flushed 8-9 months ago but won’t go down, it just keeps floating
0 · Reply
arben1
arben1 Jun. 11 at 9:10 PM
$SVRA this company it’s all about survival. Lost money years go.just stay in my watch list to see at least patient can benefit
0 · Reply
art62
art62 Jun. 4 at 10:18 PM
$SVRA "(1) SVRA expects to receive the FDA Type A meeting minutes by Aug 25, 2025, or within 90 days of the May 27 refuse-to-file (RTF) letter. Mgmt will submit a Type A meeting request within 30 days of the RTF, followed by another 30 days for the FDA to grant a meeting and an add'l 30 days for the formal meeting minutes..... we can expect SVRA to update the Street by Aug 25, 2025. SVRA has been conversing with the members of DPACC pulmonology/allergy division at CDER (vs CBER). Ultimately,... once BLA refiles in Q4:25. Our precedent analysis suggests this timeline seems doable. (2) The RTF seems related to mgmt's oversight more than anything. The FDA's requests are unrelated to any clinical trial, safety, or inconsistent CMC issues. Rather, the RTF is due to 'in-process' analytical testing being incomplete. Instead, the FDA wanted the data now. In any case, SVRA should complete in-process testing by Q3:25." tsai
0 · Reply
GoldenTradesCapital
GoldenTradesCapital Jun. 2 at 4:30 PM
Five penny stocks with great growth potential 📈 • $SPRO – Spero Therapeutics, Inc. • $SVRA – Savara Inc. • $IBRX – ImmunityBio, Inc. • $UUUU – Energy Fuels Inc. • $SPCE – Virgin Galactic Holdings, Inc.
1 · Reply
JambaPotato
JambaPotato May. 30 at 2:05 PM
$SVRA Amazing lack of management focus given the apparent efficacy of the drug and most of them with underwater substantial stock ownership now; hopefully only temporary. What possibly could be the holdup to file quickly, get this moving again within days, not months? Especially with Breakthrough Drug designation and FDA consults available.
1 · Reply
Latest News on SVRA
Savara Inc. Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm's Investigation

May 28, 2025, 6:00 AM EDT - 6 weeks ago

Savara Inc. Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm's Investigation

Why Is Rare Lung Disease-Focused Savara Stock Trading Lower On Tuesday?

May 27, 2025, 3:40 PM EDT - 6 weeks ago

Why Is Rare Lung Disease-Focused Savara Stock Trading Lower On Tuesday?

BREAKING: Savara Shares Down Over 30%; Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses

May 27, 2025, 11:42 AM EDT - 6 weeks ago

BREAKING: Savara Shares Down Over 30%; Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses

Savara Receives Refusal to File (RTF) Letter From the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for MOLBREEVI* to Treat Patients With Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP)

May 27, 2025, 8:05 AM EDT - 6 weeks ago

Savara Receives Refusal to File (RTF) Letter From the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for MOLBREEVI* to Treat Patients With Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP)

Savara Announces New Employment Inducement Grant

May 23, 2025, 4:05 PM EDT - 7 weeks ago

Savara Announces New Employment Inducement Grant

Savara Announces Participation in Jefferies Global Healthcare Conference

May 22, 2025, 9:05 AM EDT - 7 weeks ago

Savara Announces Participation in Jefferies Global Healthcare Conference

Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at American Thoracic Society Conference (ATS) 2025

May 18, 2025, 2:30 PM EDT - 7 weeks ago

Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at American Thoracic Society Conference (ATS) 2025

Savara Reports First Quarter 2025 Financial Results and Provides a Business Update

May 13, 2025, 4:05 PM EDT - 2 months ago

Savara Reports First Quarter 2025 Financial Results and Provides a Business Update

Savara Announces Participation in the H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference

May 12, 2025, 4:05 PM EDT - 2 months ago

Savara Announces Participation in the H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference

Savara Announces Participation in the Upcoming Citizens Life Sciences Conference

May 1, 2025, 4:05 PM EDT - 2 months ago

Savara Announces Participation in the Upcoming Citizens Life Sciences Conference

Savara: Make-It-Or-Break-It Molbreevi BLA Filing

Apr 21, 2025, 11:16 AM EDT - 2 months ago

Savara: Make-It-Or-Break-It Molbreevi BLA Filing

Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences

Apr 7, 2025, 4:05 PM EDT - 3 months ago

Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences

Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update

Mar 27, 2025, 7:05 AM EDT - 3 months ago

Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update

Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital

Mar 26, 2025, 4:45 PM EDT - 3 months ago

Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital

HTGC

Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Mar 26, 2025, 4:05 PM EDT - 3 months ago

Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025

Mar 17, 2025, 8:05 AM EDT - 4 months ago

Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025

Savara Announces U.S. Launch of the aPAP ClearPath™ Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Mar 6, 2025, 8:05 AM EST - 4 months ago

Savara Announces U.S. Launch of the aPAP ClearPath™ Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara Announces Participation in the Leerink Global Healthcare Conference

Mar 3, 2025, 4:15 PM EST - 4 months ago

Savara Announces Participation in the Leerink Global Healthcare Conference

Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research

Jan 30, 2025, 8:39 AM EST - 5 months ago

Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research

Savara Announces Participation in Upcoming Healthcare Investor Conferences

Jan 29, 2025, 4:05 PM EST - 5 months ago

Savara Announces Participation in Upcoming Healthcare Investor Conferences

Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Dec 18, 2024, 4:05 PM EST - 7 months ago

Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference

Dec 17, 2024, 4:05 PM EST - 7 months ago

Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference

Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024

Nov 22, 2024, 8:05 AM EST - 8 months ago

Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024

Savara Announces Participation in Upcoming Healthcare Conferences

Nov 13, 2024, 8:05 AM EST - 8 months ago

Savara Announces Participation in Upcoming Healthcare Conferences

Savara Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 12, 2024, 8:05 AM EST - 8 months ago

Savara Reports Third Quarter 2024 Financial Results and Provides Business Update

Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference

Nov 4, 2024, 4:05 PM EST - 8 months ago

Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference

Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of “The Balancing Act®” Airing on Lifetime® TV

Oct 22, 2024, 8:05 AM EDT - 9 months ago

Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of “The Balancing Act®” Airing on Lifetime® TV

Savara Announces Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting

Oct 1, 2024, 8:05 AM EDT - 10 months ago

Savara Announces Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting

Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Sep 27, 2024, 8:05 AM EDT - 10 months ago

Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately

Sep 24, 2024, 8:05 AM EDT - 10 months ago

Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately

Savara to Host Analyst and Investor Webinar on September 30, 2024

Sep 23, 2024, 8:05 AM EDT - 10 months ago

Savara to Host Analyst and Investor Webinar on September 30, 2024

Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024

Sep 8, 2024, 6:45 AM EDT - 10 months ago

Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024

Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 4:05 PM EDT - 11 months ago

Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024

Aug 15, 2024, 8:05 AM EDT - 11 months ago

Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024

Savara Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 12, 2024, 4:05 PM EDT - 11 months ago

Savara Reports Second Quarter 2024 Financial Results and Provides Business Update

Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock

Jun 28, 2024, 8:50 AM EDT - 1 year ago

Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock

Why Is Respiratory Disease-Focused Savara Stock Trading Higher On Wednesday?

Jun 26, 2024, 9:36 AM EDT - 1 year ago

Why Is Respiratory Disease-Focused Savara Stock Trading Higher On Wednesday?

Savara's rare lung disease drug meets main goal in late-stage study

Jun 26, 2024, 6:41 AM EDT - 1 year ago

Savara's rare lung disease drug meets main goal in late-stage study

Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Jun 26, 2024, 6:30 AM EDT - 1 year ago

Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Jun 25, 2024, 8:05 PM EDT - 1 year ago

Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara: The Binary Bet On Phase 3 Data

Jun 7, 2024, 5:56 AM EDT - 1 year ago

Savara: The Binary Bet On Phase 3 Data

Savara to Present at the Jefferies Global Healthcare Conference

May 29, 2024, 8:05 AM EDT - 1 year ago

Savara to Present at the Jefferies Global Healthcare Conference

Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024

May 19, 2024, 12:15 PM EDT - 1 year ago

Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024

TheThroatSlasher
TheThroatSlasher Jul. 7 at 6:20 PM
$SVRA I can’t believe this company is still operating. It’s a toilet full of diarrhea- a bowl full of liquid turds! Wipe quick & flush it
0 · Reply
Spacemonkey1
Spacemonkey1 Jul. 1 at 9:24 PM
$SVRA starting to wonder if the management team is trying to prolong things to continue getting their salaries, stock options, and bonuses.
3 · Reply
RunnerSignals
RunnerSignals Jun. 30 at 8:17 PM
comeback alert $SVRA $GMRE $CRVS $OMI $CLDX all hit the dumps midday but bounced back strong to close higher
0 · Reply
MGeronimo
MGeronimo Jun. 23 at 8:41 PM
$SVRA IN AT 2.16 on insider buying
0 · Reply
Whiskey1679
Whiskey1679 Jun. 23 at 10:57 AM
Whiskey's Picks just posted. See my Pinned post for today's picks! Premarket Gappers: $IMPP $SVRA $NNNN $SKYE $ZETA
0 · Reply
TheThroatSlasher
TheThroatSlasher Jun. 12 at 1:07 PM
$SVRA this is a turd A slippery greasy stinky turd It was flushed 8-9 months ago but won’t go down, it just keeps floating
0 · Reply
arben1
arben1 Jun. 11 at 9:10 PM
$SVRA this company it’s all about survival. Lost money years go.just stay in my watch list to see at least patient can benefit
0 · Reply
art62
art62 Jun. 4 at 10:18 PM
$SVRA "(1) SVRA expects to receive the FDA Type A meeting minutes by Aug 25, 2025, or within 90 days of the May 27 refuse-to-file (RTF) letter. Mgmt will submit a Type A meeting request within 30 days of the RTF, followed by another 30 days for the FDA to grant a meeting and an add'l 30 days for the formal meeting minutes..... we can expect SVRA to update the Street by Aug 25, 2025. SVRA has been conversing with the members of DPACC pulmonology/allergy division at CDER (vs CBER). Ultimately,... once BLA refiles in Q4:25. Our precedent analysis suggests this timeline seems doable. (2) The RTF seems related to mgmt's oversight more than anything. The FDA's requests are unrelated to any clinical trial, safety, or inconsistent CMC issues. Rather, the RTF is due to 'in-process' analytical testing being incomplete. Instead, the FDA wanted the data now. In any case, SVRA should complete in-process testing by Q3:25." tsai
0 · Reply
GoldenTradesCapital
GoldenTradesCapital Jun. 2 at 4:30 PM
Five penny stocks with great growth potential 📈 • $SPRO – Spero Therapeutics, Inc. • $SVRA – Savara Inc. • $IBRX – ImmunityBio, Inc. • $UUUU – Energy Fuels Inc. • $SPCE – Virgin Galactic Holdings, Inc.
1 · Reply
JambaPotato
JambaPotato May. 30 at 2:05 PM
$SVRA Amazing lack of management focus given the apparent efficacy of the drug and most of them with underwater substantial stock ownership now; hopefully only temporary. What possibly could be the holdup to file quickly, get this moving again within days, not months? Especially with Breakthrough Drug designation and FDA consults available.
1 · Reply
art62
art62 May. 30 at 3:41 AM
$SVRA let's face it any one of us could a more competent job than these useless scum , this company needs just maybe two or three people at most that are spending more time on FDA approval than awarding options.
0 · Reply
Spacemonkey1
Spacemonkey1 May. 29 at 9:30 PM
$SVRA my suggestion is, email Savara at [email protected], here are my questions What is the strategy to shore up investor confidence after the latest debacle? For those of us who’ve been here since the MAST merger, this latest setback is crushing. As noted by analysts, the lack of investor communication is problematic. Please address to this shareholder what went wrong? What is the plan to fix it? Why are we waiting so long to resubmit to the FDA? Why should we continue to support this management team, whose performance, frankly, does not inspire any confidence after the, latest, setback?
2 · Reply
Spacemonkey1
Spacemonkey1 May. 29 at 9:16 PM
$SVRA the only question I have is whether this is a new RFK, Jackass Fda policy trying to get people to manufacture drugs in the US. If so, that’s a disaster for the entirety of medicine and patients to delay drugsto force that
0 · Reply
Spacemonkey1
Spacemonkey1 May. 29 at 9:15 PM
$SVRA I don’t know if there is a more damning statement about the utter leadership failure that occurred. Time to cut bait. Bring in someone experienced to get over the finish line
0 · Reply
Spacemonkey1
Spacemonkey1 May. 29 at 9:13 PM
$SVRA on HC Wainwright downgrade “The analyst expressed disappointment in the lack of a clear and straightforward path forward communicated by Savara's management, especially given the drug's designation and the ongoing discussions with the FDA. Such a designation typically indicates a more interactive and positive dialogue with the agency, which should not lead to filing refusals.”
0 · Reply
RunnerSignals
RunnerSignals May. 29 at 8:32 PM
down big midday, but these comeback kings $SPTN $SVRA $TOI $HRL flipped the script and closed strong!
0 · Reply
JarvisFlow
JarvisFlow May. 29 at 11:30 AM
HC Wainwright & Co. has updated their rating for Savara ( $SVRA ) to Neutral with a price target of 2.
0 · Reply
RunnerSignals
RunnerSignals May. 29 at 3:33 AM
$SVRA watching for a pullback near $2.00. If it holds, could be setting up for a run toward $3+ risk defined, eyes open
0 · Reply
jdlman
jdlman May. 29 at 1:36 AM
$SVRA lets rock
0 · Reply
anachartanalyst
anachartanalyst May. 28 at 8:02 PM
$SVRA https://anachart.com/wp-content/uploads/ana_temp/1748462516_soc-img.jpg
1 · Reply
JarvisFlow
JarvisFlow May. 28 at 4:06 PM
Evercore ISI Group updates rating for Savara ( $SVRA ) to In-Line, target set at 3 → 2.
0 · Reply
ScottyLikeyCoffee
ScottyLikeyCoffee May. 28 at 2:58 PM
$SVRA The question was never about the drug. It works. Very little debate on that. It is all about execution. We will get there, but seemingly not before management trips on every pebble along the way.
0 · Reply